Dolutegravir: first global approval.

Article Details

Citation

Ballantyne AD, Perry CM

Dolutegravir: first global approval.

Drugs. 2013 Sep;73(14):1627-37. doi: 10.1007/s40265-013-0121-4.

PubMed ID
24052331 [ View in PubMed
]
Abstract

Dolutegravir, an orally administered HIV-1 integrase strand transfer inhibitor (INSTI), is under development by ViiV Healthcare. Like other drugs belonging in the INSTI class of antiretroviral agents, dolutegravir binds to the integrase site of HIV-1 and blocks the strand transfer integration step, thereby preventing the replication of HIV-1. Dolutegravir is being developed as an unboosted once-daily therapy for use in combination with other antiretroviral agents for the treatment of both treatment-naive and treatment-experienced patients with HIV-1 infection. Dolutegravir has been approved in the USA for the treatment of HIV-1 infection in combination with other antiretroviral agents and has been filed for approval in the EU and Canada. Phase III development is underway in North America, Europe, South Africa, South America, Australia and Taiwan. This article summarizes the milestones in the development of dolutegravir leading to this first approval for the treatment of HIV-1 infection in both therapy-naive and -experienced patients.

DrugBank Data that Cites this Article

Drugs